NovaBay Pharmaceuticals issued Notice of Allowance for broad portfolio of anti-infective compounds

NovaBay Pharmaceuticals, Inc. (NYSE Amex:NBY) (www.novabaypharma.com) announced today that it has received a Notice of Allowance from the United States Patent and Trademark Office on a patent application for a broad portfolio of anti-infective compounds, including NVC-612. The patent will broaden protection for NovaBay's first-in-class Aganocide® family of compounds, which are designed to fight infections without causing drug resistance.

The patent will cover compositions of matter and methods of use for NVC-612 and related compounds, all of which have a unique mechanism of action toward microorganisms.This new patent complements NovaBay's existing collection of more than 20 patents and pending patent applications on its proprietary technology platforms. NovaBay holds a patent for its lead anti-infective compound, NVC-422, and has a license to a broad portfolio of pending patent applications covering N-Chlorotaurine (NCT), the naturally occurring antimicrobial molecule from which NovaBay's technology is derived. NVC-422 is currently being studied in four Phase 2 clinical trials for conjunctivitis (Pink Eye), the skin infection impetigo, catheter-associated urinary tract infection, and acne.

"This latest patent will further protect NovaBay's intellectual property, as the company expands its pipeline of first-in-class non-antibiotic anti-infectives to address additional indications," said Dr. Mark Anderson, Chief Scientific Officer. "NovaBay's Aganocide compounds for treating non-systemic, topical infections are designed to rapidly fight infection without causing drug-resistance. This is increasingly important as resistance to antibiotics is becoming a growing public health concern worldwide."  

SOURCE NovaBay Pharmaceuticals, Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
bit.bio appoints Kathryn Corzo as Chief Operating Officer